Chongqing Clinical Research Center for Reproductive Medicine, Chongqing Health Center for Women and Children, Chongqing, Chongqing, China.
Chongqing Key Laboratory of Human Engineering, Center for Reproductive Medicine, Women and Children's Hospital of Chongqing Medical University, Chongqing, Chongqing, China.
BMJ Open. 2022 Nov 17;12(11):e063682. doi: 10.1136/bmjopen-2022-063682.
Accumulating evidence suggested that the laminin γ2 (LAMC2) expression level was upregulated in various cancers. However, the potential prognostic value of LAMC2 in cancers remains unclear. We conducted a meta-analysis to clarify the association of LAMC2 expression with prognosis.
We searched Embase, Web of Science and PubMed (up to 25 November 2021) to collect all eligible studies, and meta-analysis was performed to interpret the association of LAMC2 expression with clinicopathological parameters, overall survival (OS), disease-specific survival (DSS) and progression-free survival (PFS).
We included studies that investigate the relationship between LAMC2 and prognosis of cancers, patients were divided into two groups, and associations of LAMC2 expression with clinicopathological features were described.
Seven studies were finally included. We found that increased LAMC2 expression was significantly associated with lymph node metastasis (log OR 0.88, 95% CI 0.38 to 1.38, p<0.001), tumour-node-metastasis stages (log OR: 0.95, 95% CI 0.39 to 1.50, p<0.001) and tumour status (log OR 1.26, 95% CI 0.84 to 1.68, p<0.001), but not with age (log OR -0.05, 95% CI -0.37 to 0.27, p=0.75) or gender (log OR -0.07, 95% CI -0.52 to 0.38, p=0.75). In addition, higher LAMC2 expression was found to be significantly associated with OS/PFS/DSS (HR 1.85, 95% CI 1.31 to 2.40, p<0.001). A similar result was found in The Cancer Genome Atlas database. High LAMC2 expression was significantly associated with OS in lung adenocarcinoma, mesothelioma, skin cutaneous melanoma, neck squamous cell carcinoma and brain lower grade glioma.
Our results suggested that higher LAMC2 expression was correlated with worse survival, lymph node metastasis, tumour-node-metastasis stages and tumour status. This study was subject to inherent limitations, but the results presented here provide insights regarding the potential use of LAMC2 as a biomarker for human cancer.
researchregistry.com (researchregistry1319).
越来越多的证据表明，层粘连蛋白 γ2（LAMC2）的表达水平在各种癌症中上调。然而，LAMC2 在癌症中的潜在预后价值尚不清楚。我们进行了一项荟萃分析，以阐明 LAMC2 表达与预后的关系。
我们检索了 Embase、Web of Science 和 PubMed（截至 2021 年 11 月 25 日），以收集所有合格的研究，并进行荟萃分析以解释 LAMC2 表达与临床病理参数、总生存期（OS）、疾病特异性生存期（DSS）和无进展生存期（PFS）的关系。
我们纳入了研究 LAMC2 与癌症预后关系的研究，患者分为两组，并描述了 LAMC2 表达与临床病理特征的关系。
最终纳入了 7 项研究。我们发现，LAMC2 表达增加与淋巴结转移（logOR0.88，95%CI0.38 至 1.38，p<0.001）、肿瘤-淋巴结-转移分期（logOR：0.95，95%CI0.39 至 1.50，p<0.001）和肿瘤状态（logOR1.26，95%CI0.84 至 1.68，p<0.001）显著相关，但与年龄（logOR-0.05，95%CI-0.37 至 0.27，p=0.75）或性别（logOR-0.07，95%CI-0.52 至 0.38，p=0.75）无关。此外，较高的 LAMC2 表达与 OS/PFS/DSS 显著相关（HR1.85，95%CI1.31 至 2.40，p<0.001）。在 The Cancer Genome Atlas 数据库中也得到了类似的结果。在肺腺癌、间皮瘤、皮肤黑色素瘤、颈部鳞状细胞癌和脑低级别胶质瘤中，高 LAMC2 表达与 OS 显著相关。
我们的结果表明，较高的 LAMC2 表达与较差的生存、淋巴结转移、肿瘤-淋巴结-转移分期和肿瘤状态相关。本研究存在固有局限性，但本研究结果为 LAMC2 作为人类癌症的潜在生物标志物提供了新的见解。
researchregistry.com（researchregistry1319）。
